---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061441"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:19:04.502950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance

## Summary
- Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).
- Proprietary net sales $244.5M (+5% YoY); LYBALVI grew 23% to $70.0M, VIVITROL $101.0M, ARISTADA $73.5M.
- Cash and investments $916.2M, up from $824.8M at Dec. 31, 2024.
- ALKS 2680 phase 2 Vibrance-1 enrollment complete; topline data expected early Q3 2025.
- Company reiterates full-year 2025 financial expectations as communicated Feb. 12, 2025.

## SEC filing metadata
- accession: 0000950170-25-061441
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/0000950170-25-061441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/alks-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061441
- JSON: https://secwatch.observer/filing/0000950170-25-061441.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.